For Doctors in a Hurry
- Clinicians often struggle to determine if patients with ptosis meet insurance criteria for surgical correction using traditional eyelid taping.
- The researchers evaluated 27 eyes with ptosis by comparing baseline measurements, manual eyelid taping, and phenylephrine 2.5 percent ophthalmic solution.
- Phenylephrine increased the margin reflex distance by a mean of 1.33 millimeters, with a 95 percent confidence interval of 1.09 to 1.57.
- The study concluded that phenylephrine provides comparable visual field improvements to taping while significantly increasing patient satisfaction scores.
- Physicians may consider using phenylephrine drops as a more comfortable alternative to manual taping when assessing insurance eligibility for surgery.
Refining the Preoperative Assessment of Acquired Blepharoptosis
Acquired blepharoptosis is a common clinical presentation characterized by a drooping upper eyelid that restricts the superior visual field and impairs daily functioning [1]. For many patients, the preferred intervention is a Müller muscle-conjunctival resection, which is a posterior-approach surgical procedure that shortens the eyelid elevators from the underside of the lid [2, 3]. Clinicians often utilize a preoperative phenylephrine test to gauge the potential for eyelid elevation, yet insurance providers typically require objective evidence of functional impairment through visual field testing. Traditionally, this documentation involves mechanical eyelid taping to simulate surgical outcomes. While topical alpha-adrenergic agonists, which are medications that stimulate specific receptors to contract the Müller muscle and lift the lid, such as oxymetazoline 0.1%, are used for non-surgical management, their role in the diagnostic workup is evolving [4, 5, 6]. A recent study evaluates whether pharmacological elevation can serve as a reliable, patient-friendly alternative to manual taping for these essential preoperative assessments.
Comparing Pharmacological and Mechanical Eyelid Elevation
The researchers employed a single-arm, sequential study design, which is a research framework where all participants receive the same interventions in a specific order, allowing each patient to serve as their own control. The study included 27 eyes with visually significant ptosis to determine if pharmacological intervention could replace mechanical taping for insurance qualification. Each eye was evaluated under three conditions: at baseline, following manual eyelid taping, and after the instillation of phenylephrine 2.5% ophthalmic solution. This design allowed for a direct comparison between the physiological response of the Müller muscle and the traditional mechanical elevation used to simulate surgical results. The trial is registered at ClinicalTrials.gov under the identifier NCT05890027.
To assess efficacy, the study utilized two primary clinical metrics. The first was the change in margin reflex distance 1, which is the vertical distance between the center of the pupillary light reflex and the edge of the upper eyelid margin. The second was the expansion of the superior visual field, measured via tangent screen visual field testing, a manual method of mapping peripheral vision using a flat screen to identify exactly where a patient's vision is obstructed. Beyond these objective measures, participants completed a poststudy questionnaire to quantify their subjective experience and comfort levels with both the taping and pharmacological methods.
Equivalent Visual Field Gains and Insurance Eligibility
The findings indicate that phenylephrine 2.5% ophthalmic solution effectively replicates the visual field expansion required for surgical authorization. From a mean baseline of 6.85 degrees, the mean superior visual field improved to 21.77 degrees with manual eyelid taping and to 22.56 degrees following phenylephrine instillation. This pharmacological approach proved highly effective in meeting the standard insurance criterion, which requires a minimum increase of 12 degrees in the superior visual field for reimbursement. Specifically, 92.5% of eyes met the insurance threshold with phenylephrine, compared to 88.8% of eyes using the manual taping method. Statistical analysis confirmed no significant difference in the proportion of eyes meeting these reimbursement criteria between the two techniques (p = 1.000).
Anatomical measurements also showed significant changes following pharmacological intervention. The margin reflex distance 1 increased from a mean baseline of 0.83 mm to 2.17 mm after phenylephrine instillation, representing a mean improvement of 1.33 mm (95% confidence interval: 1.09 to 1.57 mm, p < 0.001). However, the researchers observed that changes in margin reflex distance 1 and visual field expansion after phenylephrine instillation showed no positive correlation (rs = 0.13, p > 0.05). This lack of a statistically significant relationship suggests that the physical height of the eyelid does not always serve as a linear predictor of functional visual gain, a finding that has direct implications for how clinicians document impairment.
Clinical Implications of Eyelid Height and Patient Preference
The disconnect between anatomical elevation and functional improvement is a critical takeaway for practicing physicians. Because changes in margin reflex distance 1 and visual field after phenylephrine instillation showed no positive correlation (rs = 0.13, p > 0.05), clinicians cannot rely solely on the physical lift of the eyelid margin to estimate how much a patient's vision has improved. For the practicing ophthalmologist, this underscores the necessity of performing formal visual field testing rather than using eyelid height as a surrogate measure when documenting the functional impact of ptosis for insurance purposes. Relying on visual inspection alone may lead to an underestimation or overestimation of the actual functional benefit the patient receives.
Furthermore, the study highlighted a significant difference in the patient experience during diagnostic testing. Patient satisfaction scores were significantly higher with phenylephrine (4.26 ± 0.81) compared with manual taping (3.67 ± 0.48), with a mean difference of 0.59 (p < 0.001). Manual eyelid taping is often associated with skin irritation or a pulling sensation on the delicate periorbital tissue, whereas the instillation of a 2.5% phenylephrine solution is less invasive. Given that phenylephrine provides visual field gains comparable to taping while achieving higher patient satisfaction, it represents a viable and more comfortable alternative for preoperative documentation and surgical planning in the clinical setting.
References
1. Bacharach J, Lee WW, Harrison AR, Freddo TF. A review of acquired blepharoptosis: prevalence, diagnosis, and current treatment options. Eye. 2021. doi:10.1038/s41433-021-01547-5
2. Fatani DR, Kamal YF, AlSulaiman HM. Müller muscle-Conjunctival Resection (MMCR) Surgery: A Comprehensive Literature Review.. European journal of ophthalmology. 2025. doi:10.1177/11206721241249505
3. Nowak‐Gospodarowicz I, Kinasz M, Kicińska AK, Rękas M. An update on posterior-approach blepharoptosis surgery: Influence of clinical factors on surgical outcomes. PLoS ONE. 2026. doi:10.1371/journal.pone.0343505
4. Bawazir R, Qedair J, Bukhari ZM, et al. Efficacy of Oxymetazoline 0.1% in Acquired Blepharoptosis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Clinical ophthalmology. 2025. doi:10.2147/opth.s529633
5. Bacharach J, Wirta D, Smyth-Medina R, et al. Rapid and Sustained Eyelid Elevation in Acquired Blepharoptosis with Oxymetazoline 0.1%: Randomized Phase 3 Trial Results. Clinical ophthalmology. 2021. doi:10.2147/opth.s306155
6. Wirta D, Korenfeld M, Foster S, et al. Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials. Clinical ophthalmology. 2021. doi:10.2147/opth.s322326
